Products are packed and if necessary repacked with utmost care and precaution, the purpose is to minimize shipment volume and discretion. Our organization name or anything else that would imply pharmaceutical contents of the package is never used in our shipments. The size of our packages is never larger than what would cause unnecessary suspicion. If the order is too large to fit one of these packages, the order will automatically be divided into two or more packages (always included in the S&H-charges). Shipments are made from various shipping points in different European countries.
2. Does the morbiditiy and mortality assocaited with a miss of a % of PEs = % of patients with acute coronary syndrome. More specificcally, since we know STEMIs have bad outcomes – does % of missed PEs = % of missed NSTEMI/UA??? I’d imagine a small PE doesn’t likely cause much morbidity or mortality in patients (ie the PEs that PERC likely misses). However, does a missed NSTEMI/UA cause significant morbidity and mortality? I don’t know that answer, but I rememeber listening to Dr Newman in EM-RAP talking about the cochrane review on heparin for NSTEMI that did not show much difference between risks and benefits? Moreover, is medical mgmt what these patient’s really need or does heparin followed by stents really offer these patients much benefit? That brings me back to #1. If the adverse events were missed NSTEMI or UA,and studies have shown that inpt hospital mgmt doesn’t change outcomes, then I’m starting to use this ASPECT trial tomorrow.